SAVE Act of 2023

To amend the Defense Production Act of 1950 to ensure the supply of certain medical materials essential to national defense, and for other purposes. 1. Short title This Act may be cited as the Securing America’s Vaccines for Emergencies Act of 2023 SAVE Act of 2023 2. Securing essential medical materials (a) Statement of policy Section 2(b) of the Defense Production Act of 1950 ( 50 U.S.C. 4502 (1) by redesignating paragraphs (3) through (8) as paragraphs (4) through (9), respectively; and (2) by inserting after paragraph (2) the following: (3) authorities under this Act should be used when appropriate to ensure the availability of medical materials essential to national defense, including through measures designed to secure the drug supply chain, and taking into consideration the importance of United States competitiveness, scientific leadership and cooperation, and innovative capacity; . (b) Strengthening domestic capability Section 107 of the Defense Production Act of 1950 ( 50 U.S.C. 4517 (1) in subsection (a), by inserting (including medical materials) materials (2) in subsection (b)(1), by inserting (including medical materials such as drugs (as defined under the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq. 42 U.S.C. 262 essential materials (c) Strategy on securing supply chains for medical materials Title I of the Defense Production Act of 1950 ( 50 U.S.C. 4511 et seq. 109. Strategy on securing supply chains for medical materials (a) In general Not later than 180 days after the date of the enactment of this section, the President, in consultation with the Secretary of Health and Human Services, the Secretary of Commerce, the Secretary of Homeland Security, and the Secretary of Defense, shall transmit a strategy to the appropriate Members of Congress that includes the following: (1) A detailed plan to use the authorities under this title and title III, or any other provision of law, to ensure the supply of medical materials (including drugs (as defined under the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq. 42 U.S.C. 262 (2) An analysis of vulnerabilities to existing supply chains for such medical materials, and recommendations to address the vulnerabilities. (3) Measures to be undertaken by the President to diversify such supply chains, as appropriate and as required for national defense. (4) A discussion of— (A) any significant effects resulting from the plan and measures described in this subsection on the production, cost, or distribution of biological products or any other devices or drugs; (B) a timeline to ensure that essential components of the supply chain for medical materials are not under the exclusive control of a foreign government in a manner that the President determines could threaten the national defense of the United States; and (C) efforts to mitigate any risks resulting from the plan and measures described in this subsection to United States competitiveness, scientific leadership, and innovative capacity, including efforts to cooperate and proactively engage with United States allies. (b) Progress Report Following submission of the strategy under subsection (a), the President shall submit to the appropriate Members of Congress an annual progress report until September 30, 2027, evaluating the implementation of the strategy, and may include updates to the strategy as appropriate. The strategy and progress reports shall be submitted in unclassified form but may contain a classified annex. (c) Appropriate Members of Congress In this section, the term appropriate Members of Congress . 3. Investment in supply chain security (a) In general Section 303 of the Defense Production Act of 1950 ( 50 U.S.C. 4533 (h) Investment in supply chain security (1) In general In addition to other authorities in this title, the President may make available to an eligible entity described in paragraph (2) payments to increase the security of supply chains and supply chain activities, if the President certifies to Congress not less than 30 days before making such a payment that the payment is critical to meet national defense requirements of the United States. (2) Eligible entity An eligible entity described in this paragraph is an entity that— (A) is organized under the laws of the United States or any jurisdiction within the United States; and (B) produces— (i) one or more critical components; (ii) critical technology; or (iii) one or more products or raw materials for the security of supply chains or supply chain activities. (3) Definitions In this subsection, the terms supply chain supply chain activities . (b) Regulations (1) In general Not later than 90 days after the date of the enactment of this Act, the President shall prescribe regulations setting forth definitions for the terms supply chain supply chain activities 50 U.S.C. 4533(h) (2) Scope of definitions The definitions required by paragraph (1)— (A) shall encompass— (i) the organizations, people, activities, information, and resources involved in the delivery and operation of a product or service used by the Government; or (ii) critical infrastructure as defined in Presidential Policy Directive 21 (February 12, 2013; relating to critical infrastructure security and resilience); and (B) may include variations as determined necessary and appropriate by the President for purposes of national defense. May 23, 2024 Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed

Summary: Securing America's Vaccines for Emergencies Act of 2023 or the SAVE Act of 2023 This bill authorizes the President to make payments to manufacturers to increase supply-chain security if doing so is important to the national defense. The President must submit a strategy to Congress that includes (1) a plan to use authorities under the Defense Production Act of 1950 to ensure the supply of medical materials essential to the national defense; and (2) plans to diversify, and address vulnerabilities in, supply chains for essential medical materials. The President must submit to Congress annual progress reports through FY2025 evaluating the implementation of the strategy.